Lingying Wu, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Junying Tang, Guonan Zhang, Min Hao, Desheng Yao, Qinglei Gao, Youzhong Zhang, Ruifang An, Rutie Yin, Li Wang, Bairong Xia, Qi Zhou, Hongying Yang, Jianqing Zhu, Kui Jiang, Zhengzheng Chen, Qiang Wu, Wei Duan, Yi Huang, Hui Zhang, Shuqing Wei, Guiling Li, Yuanguang Meng, Ke Wang, Xinfeng Yang, Xianghua Huang, Lingya Pan, Jinjin Yu, Ge Lou, Yu Zhang, Huaijun Zhou, Xiaoqing Guo, Hong Yang, Xiaodong Cheng, Xiumin Li, Wuliang Wang, Hongqin Zhao, Yunxia Li, Yingjie Yang, An Lin, Wenjun Cheng, Lihong Chen, Xiaoying Xie, Wen Di, Yuanjing Hu, Mo Chen, Hongwu Wen, Liping Cai, Xiaohua Wu, Zhongqiu Lin, Quanren Wang. "Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial." CA: A Cancer Journal for Clinicians (2026). https://doi.org/10.3322/caac.70042